tuxobertinib   Click here for help

GtoPdb Ligand ID: 11676

Synonyms: BDTX-189 | BDTX189 | example 8 [US11034672B1]
Compound class: Synthetic organic
Comment: We obtained the chemical structure for tuxobertinib from WHO Proposed list 125. This mapped to PubChem CID 154824631. Tuxobertinib (BDTX-189) is an irreversible, orally active, ATP-competitive EGFR/HER2 inhibitor. It is being developed by Black Diamond Therapeutics as a therapy for cancers that are driven by oncogenic allosteric, activating mutations of the EGFR and ErbB2 (HER2). It was designed to minimize EGFR-WT mediated toxicities. Tuxobertinib is one of the examples claimed in patent US11034672B1 [1].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 12
Topological polar surface area 110.73
Molecular weight 560.19
XLogP 3.02
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES C=CC(=O)Nc1cc2c(ncnc2cc1OCCN1CCOCC1)Nc1ccc(c(c1)Cl)OCc1ccccn1
Isomeric SMILES C=CC(=O)Nc1c(cc2c(c1)c(ncn2)Nc1cc(c(cc1)OCc1ccccn1)Cl)OCCN1CCOCC1
InChI InChI=1S/C29H29ClN6O4/c1-2-28(37)35-25-16-22-24(17-27(25)39-14-11-36-9-12-38-13-10-36)32-19-33-29(22)34-20-6-7-26(23(30)15-20)40-18-21-5-3-4-8-31-21/h2-8,15-17,19H,1,9-14,18H2,(H,35,37)(H,32,33,34)
InChI Key HIBPKFXWOPYJPZ-UHFFFAOYSA-N
References
1. Flohr A, Mayweg A, Trainor G, Epstein DM, O'Connor M, Buck E, Arista L. (2021)
Tyrosine kinase inhibitor compositions, methods of making and methods of use.
Patent number: US11034672B1. Assignee: Black Diamond Therapeutics Inc. Priority date: 25/09/2018. Publication date: 15/06/2021.